Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MD › Greenbelt › NPI 1225001654

The Retina Group of Washington, PLLC

The Retina Group of Washington, PLLC was paid $19.61M by Medicaid between Jan 2018 and Dec 2024, across 33 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 53% of everything it billed.

33Billing provider infoTHE RETINA GROUP OF WASHINGTON, PLLC
GREENBELT, MD 20770
33aNPI1225001654assigned 02/08/2006
33bProvider typeOptometrist
28Total paid$19.61M
24GClaims369,283
24DCodes billed33
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Optometrist providers in Maryland

Rank by total paid#1 of 345
Median peer was paid$27K
This provider vs. median720×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201831,948$511K
201945,797$853K
202039,725$1.33M
202156,248$2.38M
202272,779$4.40M
202371,207$5.78M
2024incomplete51,579$4.35M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
J0178 Injection, aflibercept, 1 mg 53% 15,254 12,226 $10.45M
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient 14% 77,410 64,093 $2.65M
92134 8.8% 106,803 88,950 $1.73M
67028 Intravitreal injection of a pharmacologic agent 6.0% 37,853 30,312 $1.18M
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5.4% 18,081 15,228 $1.07M
J2778 Injection, ranibizumab, 0.1 mg 2.5% 1,880 1,504 $482K
92202 2.4% 55,977 47,688 $469K
J0177 Injection, aflibercept hd, 1 mg 1.8% 485 474 $343K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 1.6% 4,635 4,121 $317K
J2777 Injection, faricimab-svoa, 0.1 mg <1% 295 270 $149K
J3590 Unclassified biologics <1% 202 191 $138K
92201 <1% 7,474 6,386 $122K
21 more codes
J9035 Injection, bevacizumab, 10 mg <1% 3,930 $115K
92250 <1% 4,223 $101K
92235 <1% 2,893 $83K
J7999 Compounded drug, not otherwise classified <1% 1,259 $78K
92226 <1% 25,222 $60K
Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg <1% 58 $22K
67228 <1% 79 $12K
92225 <1% 2,457 $12K
76512 <1% 794 $9K
92133 <1% 455 $8K
92004 Ophthalmological services: medical examination and evaluation, comprehensive, new patient <1% 339 $7K
99213 Doctor's office visit, returning patient (routine) <1% 214 $6K
92012 Ophthalmological services: medical examination and evaluation, intermediate, established patient <1% 335 $2K
92287 <1% 68 $2K
92083 <1% 146 $1K
99203 Doctor's office visit, new patient (routine) <1% 28 $1K
92015 Determination of refractive state <1% 143 $677.57
92020 <1% 14 $264.65
92136 <1% 27 $144.73
99426 0% 208 $0.00
99427 0% 42 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMADREPERLA, STEVEN (PRESIDENT AND CEO)
Same official

Other billing entities under MADREPERLA, STEVEN

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.